NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
IntroductionMultiple System Atrophy (MSA) is a rare, sporadic, age-related synucleinopathy characterized by Parkinson-like motor symptoms and ataxia. There is no therapy for MSA other than symptomatic treatment. MSA is characterized pathologically by glial cytoplasmic inclusions (GCI) of α-synuclein (αSyn) occurring in oligodendrocytes leading to loss of myelination in the brain.MethodsWe recently utilized a peptide-mediated delivery method to systemically transport an anti-sense oligonucleotide (ASO) targeted to αSyn in a mouse model of MSA. We hypothesized that systemic delivery of αSyn ASO by peptide mediated delivery to a mouse model of MSA would reduce the αSyn accumulation in oligodendrocytes and reduce the overt pathology associated with MSA.ResultsFollowing monthly treatments of the αSyn ASO, we found increased myelination in the corpus callosum, cerebellum and brainstem. We also observed increased numbers of oligodendrocytes and reduced gliosis; however, we did not detect changes in overall αSyn in the areas of the brain we examined. Upon further analysis, we determined the peptide-mediated delivery of αSyn ASO was not taken up by oligodendrocytes.ConclusionThus, we have successfully alleviated some of the pathology associated with MSA in a mouse model; however, without direct delivery to oligodendrocytes, other approaches may need to supplement this therapy.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.